Wells Fargo & Company Angion Biomedica Corp. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.48 - $1.02 $0 - $2	2 Added 1.37%	148 $0
Q4 2022 Feb 13, 2023	BUY	$0.8 - $1.0 $4 - $5	5 Added 3.55%	146 $0
Q3 2022 Nov 14, 2022	SELL	$0.94 - $1.23 $40 - $52	-43 Reduced 23.37%	141 $0
Q2 2022 Aug 12, 2022	SELL	$1.1 - $2.23 $5,251 - $10,646	-4,774 Reduced 96.29%	184 $0
Q1 2022 May 16, 2022	SELL	$1.72 - $2.96 $20,025 - $34,463	-11,643 Reduced 70.13%	4,958 $10,000

Q4 2021 Feb 14, 2022	BUY	$2.35 - $9.95 $38,582 - $163,359	16,418 Added 8971.58%	16,601 $48,000
Q3 2021 Nov 15, 2021	BUY	$9.31 - $13.25 $772 - $1,099	83 Added 83.0%	183 $2,000
Q2 2021 Aug 16, 2021	SELL	$13.02 - $17.83 $23,566 - $32,272	-1,810 Reduced 94.76%	100 $1,000
Q1 2021 May 13, 2021	BUY	$15.01 - $25.74 $28,669 - $49,163	1,910 New	1,910 $35,000

Ticker ANGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,113,300
Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.